Associated Papers
Inhibition or genetic reduction of ASAH1/acid ceramidase restore α-synuclein clearance in mutant GBA1 dopamine neurons from Parkinson's patients.
Kumar M et al.
Human Molecular Genetics, 2025
41224733 (PubMed )
Supplement: supplemental_figure_legends_ddaf166.docx
GBA-AAV mitigates sleep disruptions and motor deficits in mice with REM sleep behavior disorder.
Chen Y et al.
Npj Parkinson's Disease, 2024
Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy.
Kuo SH et al.
Science Advances, 2022
Comparative Transcriptome Analysis in Monocyte-Derived Macrophages of Asymptomatic GBA Mutation Carriers and Patients with GBA-Associated Parkinson's Disease.
Usenko T et al.
Genes, 2021
Modelling Parkinson's Disease: iPSCs towards Better Understanding of Human Pathology.
Avazzadeh S et al.
Brain Sciences, 2021
Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells.
Tran J et al.
Npj Parkinson's Disease, 2020
Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity.
Mus L et al.
Neurobiology of Disease, 2019
α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.
Yun SP et al.
Molecular Neurodegeneration, 2018
29310663 (PubMed )
Supplement: 13024_2017_233_MOESM8_ESM.pdf
Mitochondria: A Common Target for Genetic Mutations and Environmental Toxicants in Parkinson's Disease.
Helley MP et al.
Frontiers in Genetics, 2017
Select a paper to view details